|
Sio Gene Therapies Inc (NASDAQ: SIOX) |
|
Sio Gene Therapies Inc
SIOX's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Sio Gene Therapies Inc 's sales fell
in the third quarter of 2022 from the same quarter a year ago.
Major Pharmaceutical Preparations industry recorded
deterioration of revenues by -2.27 %
Sio Gene Therapies Inc net loss decreased from $-25 millions, to $-4 millions in third quarter of 2022,
• More on SIOX's Growth
|
|
Sio Gene Therapies Inc realized a net loss in trailing twelve months.
Sio Gene Therapies Inc realized cash reduction of $ -0.5 per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.46.
• More on SIOX's Valuation
|
|
|
|
|
Sio Gene Therapies Inc realized net loss in trailing twelve months.
Sio Gene Therapies Inc realized cash outflow of $ -0.5per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.46.
Sio Gene Therapies Inc Price to Book Ratio is at 0.78 lower than Industry Avg. of 34.92. and higher than S&P 500 Avg. of 0.01
• More on SIOX's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com